We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Curetis

Curetis GmbH develops and commercializes molecular diagnostic products that are designed to address the global challe... read more Featured Products: More products

Download Mobile App




Rapid Molecular Diagnostics Platform Uses Multiplex PCR Technology for Fast Diagnosis of Severe Infectious Diseases

By LabMedica International staff writers
Posted on 20 Apr 2023
Print article
Image: The Unyvero A50 System can process two cartridges independently with full random-access capabilities (Photo courtesy of Curetis)
Image: The Unyvero A50 System can process two cartridges independently with full random-access capabilities (Photo courtesy of Curetis)

In order to improve patient outcomes in cases of bacterial co-infections like severe pneumonia, rapid detection of pathogens and associated resistance markers is crucial to guide appropriate antibiotic treatment. Now, a cutting-edge molecular diagnostic platform can reliably and accurately diagnose severe infectious diseases by using multiplex PCR technology to detect a wide range of microorganisms, antibiotic resistance markers, or toxins from sample-to-answer within 4-5 hours.

Curetis GmbH’s (Holzgerlingen, Germany) Unyvero A50 system is designed to support various applications for diagnosing severe infectious diseases through syndromic testing. The Unyvero A50 system offers five panels to test for Hospitalized Pneumonia (HPN), Blood Stream Infections (BCU), Implant & Tissue Infections (ITI), Intra-Abdominal Infections (IAI), and Urinary Tract Infections (UTI). Unyvero's multiplex diagnostic panels employ a molecular approach using multiplex PCR technology to detect a wide range of clinically relevant microorganisms and antibiotic resistance markers. This allows for the rapid and accurate identification of infectious agents within less than five hours. The ability to concurrently detect various clinically relevant microorganisms and antibiotic resistance in a single test facilitates prompt identification of likely pathogens and more rapid, targeted antibiotic selection.

The Unyvero multiplex diagnostic panels include the Unyvero Hospitalized Pneumonia (HPN) Cartridge, which tests for 38 reportable targets (21 pathogens and 17 resistance genes) within 4-5 hours, enabling targeted syndromic treatment during the critical early hours of infection. The Unyvero panel range also features the Unyvero Implant & Tissue Infection (ITI) Cartridge, which tests for 46 reportable targets (29 pathogens and 17 resistance genes) and delivers results with high sensitivity and specificity within 4-5 hours. This test panel allows physicians to swiftly diagnose infections and determine the most effective treatment.

Additionally, the Unyvero multiplex diagnostic panels include the Unyvero Blood Culture (BCU) Cartridge for positive blood cultures, testing for 50 reportable targets (34 pathogens and 16 resistance genes) with a single sample, delivering results with high sensitivity and specificity within 4-5 hours. Additionally, the panels range features the Unyvero Intra-Abdominal Infection (IAI) Cartridge, which tests for 50 targets (26 pathogens, 2 toxins, and 22 resistance genes) with a 4-5 hour sample-to-answer time. Based on this comprehensive analysis, physicians can promptly decide on the most suitable treatment path, resulting in improved outcomes, reduced hospital stays, and decreased healthcare costs.

Related Links:
Curetis GmbH

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.